Knowledge mapping of immunotherapy for breast cancer: A bibliometric analysis from 2013 to 2022

Human Vaccines & Immunotherapeutics, Год журнала: 2024, Номер 20(1)

Опубликована: Апрель 2, 2024

Breast cancer is the leading cause of cancer-related death among women globally. Immunotherapy has emerged as a major milestone in contemporary oncology. This study aims to conduct bibliometric analysis field immunotherapy for breast cancer, providing comprehensive overview current research status, identifying trends and hotspots topics. We searched retrieved data from Web Science Core Collection, performed publications on 2013 2022. Current status were evaluated by co-occurrence using VOSviewer. Evolution bursts knowledge base assessed co-citation CiteSpace. Thematic evolution bibliometrix package was used discover keywords trends. The attribution collaboration countries/regions, institutions authors also explored. A total 7,975 included. In keywords, 6 clusters revealed: tumor microenvironment, prognosis biomarker, immune checkpoints, novel drug delivery methods, cells therapeutic approaches. top three most frequently mentioned triple-negative programmed cell ligand 1. productive country, institution author USA (2926 publications), University Texas MD Anderson Cancer Center (219 Sherene Loi (28 respectively. There been rapid growth studies worldwide. area gained increasing attention different countries institutions. With rising incidence represents significant clinical value potential.

Язык: Английский

---

Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation

Nature Communications, Год журнала: 2020, Номер 11(1)

Опубликована: Июль 30, 2020

Abstract Most triple-negative breast cancer (TNBC) patients fail to respond T cell-mediated immunotherapies. Unfortunately, the molecular determinants are still poorly understood. Breast is disease genetically linked a deficiency in autophagy. Here, we show that autophagy defects TNBC cells inhibit tumour killing vitro and vivo. Mechanistically, identify Tenascin-C as candidate for deficiency-mediated immunosuppression, which Lys63-ubiquitinated by Skp2, particularly at Lys942 Lys1882, thus promoting its recognition p62 leading selective autophagic degradation. High expression associated with poor prognosis inversely correlated LC3B CD8 + patients. More importantly, inhibition of autophagy-impaired sensitizes improves antitumour effects single anti-PD1/PDL1 therapy. Our results provide potential strategy targeting combination blockade immune checkpoint inhibitors.

Язык: Английский

---

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer

Frontiers in Oncology, Год журнала: 2021, Номер 11

Опубликована: Окт. 28, 2021

Triple-negative breast cancer (TNBC) is the most aggressive subtype of cancer, which characterized by absence estrogen receptor (ER) and progesterone (PR) expression human epidermal growth factor 2 (HER2) expression/amplification. Conventional chemotherapy mainstay systemic treatment for TNBC. However, lack molecular targeted therapies poor prognosis TNBC patients have prompted a great effort to discover effective targets improving clinical outcomes. For now, poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi’s) immune checkpoint been approved Moreover, agents that target signal transduction, angiogenesis, epigenetic modifications, cell cycle are under active preclinical or investigations. In this review, we highlight current major developments in TNBC, with some descriptions about their (dis)advantages future perspectives.

Язык: Английский

---

Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects

Expert Opinion on Investigational Drugs, Год журнала: 2021, Номер 31(6), С. 557 - 565

Опубликована: Ноя. 22, 2021

Introduction Immune checkpoint inhibitor (ICI) monotherapy appears to be effective in a small cohort of patients with metastatic triple negative breast cancer (mTNBC). This supports the exploration strategies for increasing efficacy immunotherapy. To enhance overall response and clinical outcomes, several immune-based combinations are being investigated.Areas covered The authors present synopsis current, state-of-art this setting reflect on future possibilities. They shed light recently presented published trials ongoing studies. A literature search was conducted October 2021; addition, abstracts international meetings were reviewed.Expert opinion Clinical suggest that ICI could beneficial minority mTNBC patients; conversely, have reported notable results or Some these combination been approved – as case chemoimmunotherapy PD-L1 positive patients. Numerous investigating novel ICI-based their eagerly awaited.

Язык: Английский

---

Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)

Oncology Letters, Год журнала: 2021, Номер 22(1)

Опубликована: Май 5, 2021

Breast cancer is the most prevalent in women worldwide. Triple‑negative breast (TNBC) characterized by lack of expression estrogen receptor, progesterone and human epidermal growth factor receptor 2. It aggressive subtype accounts for 12‑20% all cases. TNBC associated with younger age onset, greater metastatic potential, higher incidence relapse, lower overall survival rates. Based on molecular phenotype, has been classified into six subtypes (BL1, BL2, M, MES, LAR, IM). treatment challenging due to its heterogeneity, highly invasive nature, relatively poor therapeutics response. Chemotherapy radiotherapy are conventional strategies TNBC. Recent research mechanistic understanding disease pathogenesis using cutting‑edge technologies led unfolding new lines therapies that have incorporated clinical practice. Poly (ADP‑ribose) polymerase immune checkpoint inhibitors made their way current paradigm. This review focuses classification, features, progress Histological connected recurrence, classification TNBC, targeted therapy early advanced advances non‑coding RNA key highlights this review.

Язык: Английский

---

Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(23), С. 14937 - 14937

Опубликована: Ноя. 29, 2022

Heterogeneity of triple-negative breast cancer is well known at clinical, histopathological, and molecular levels. Genomic instability greater mutation rates, which may result in the creation neoantigens enhanced immunogenicity, are additional characteristics this type. Clinical outcome poor due to early age onset, high metastatic potential, increased likelihood distant recurrence. Consequently, efforts elucidate mechanisms development, progression, spread have been initiated improve treatment options outcomes for these patients. The extremely complex heterogeneous tumor immune microenvironment made up several cell types commonly possesses disorganized gene expression. Altered signaling pathways mainly associated with mutated genes including p53, PIK3CA, MAPK, positively correlated regulating response. Of note, particular immunity-associated could be used prognostic indexes assess most effective management. Recent findings highlight fact that long non-coding RNAs also play an important role shaping formation, can mediate evasion. Identification signatures, through use multi-omics approaches, effector drive stages carcinogenic process steps developing new strategies targeted prevention. Advances immunotherapy by remodeling host system eradicate cells great promise lead novel therapeutic strategies. Current research focused on combining checkpoint inhibition chemotherapy, PARP inhibitors, vaccines, or natural killer therapy. Targeted therapies response, eliminate resistance, overall patient survival. In future, evolving advancements should implemented personalized medicine state-of-art management

Язык: Английский

---

Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic/chemo-/immunotherapy

Bioactive Materials, Год журнала: 2022, Номер 20, С. 548 - 560

Опубликована: Июнь 29, 2022

Bacterial outer membrane vesicles (OMVs) are potent immuno-stimulating agents and have the potentials to be bioengineered as platforms for antitumor nanomedicine. In this study, OMVs demonstrated promising therapeutics. can lead beneficial M2-to-M1 polarization of macrophages induce pyroptosis enhance immunity, but therapeutic window is narrow its toxicity. We propose a bioengineering strategy tumor-targeting ability by macrophage-mediated delivery improve efficacy co-loading photosensitizer chlorin e6 (Ce6) chemotherapeutic drug doxorubicin (DOX) into platform. demonstrate that systemic injection DOX/Ce6-OMVs@M platform, providing combinational photodynamic/chemo-/immunotherapy, eradicates triple-negative breast tumors in mice without side effects. Importantly, also effectively prevents tumor metastasis lung. This OMVs-based with may serve powerful platform synergic therapy.

Язык: Английский

---

Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer

Journal of Nanobiotechnology, Год журнала: 2021, Номер 19(1)

Опубликована: Май 19, 2021

Abstract Background Triple negative breast cancer (TNBC) is an aggressive tumor with extremely high mortality that results from its lack of effective therapeutic targets. As adhesion molecule related to tumorigenesis and metastasis, cluster differentiation-44 (also known as CD44) overexpressed in TNBC. Moreover, CD44 can be effectively targeted by a specific hyaluronic acid analog, namely, chitosan oligosaccharide (CO). In this study, CO-coated liposome was designed, Photochlor (HPPH) the 660 nm light mediated photosensitizer evofosfamide TH302) hypoxia-activated prodrug. The obtained liposomes help diagnose TNBC fluorescence imaging produce antitumor therapy synergetic photodynamic (PDT) chemotherapy. Results Compared nontargeted liposomes, exhibited good biocompatibility targeting capability vitro; vivo, much better capability. Additionally, loaded HPPH TH302 showed significantly effects than other monotherapy groups both vitro vivo. Conclusion impressive synergistic effects, together superior capability, minor side confers potential for future translational research diagnosis CD44-overexpressing therapy, especially Graphic abstract

Язык: Английский

---

KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer

Future Oncology, Год журнала: 2022, Номер 18(18), С. 2301 - 2309

Опубликована: Апрель 5, 2022

Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new diagnoses early cancer. Novel systemic treatment options have recently been assessed as part the neoadjuvant approach, such addition immune checkpoint inhibitors to cytotoxic chemotherapy. However, several questions remain unanswered, including identification predictors response immunotherapy in this setting, and further efforts aimed at identifying reliable clarifying effective role PD-L1 status, tumor mutational burden, tumor-infiltrating lymphocytes other biomarkers are warranted. Herein we will provide an overview recent clinical studies patients with cancer, especially focusing on presented published KEYNOTE-522, IMpassion031 GeparNUEVO trials.

Язык: Английский

---

High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases

BMC Bioinformatics, Год журнала: 2022, Номер 23(1)

Опубликована: Авг. 22, 2022

Abstract Cuproptosis induction represents a promising alternative for immunotherapies and targeted therapies in breast cancer. This study aimed to investigate the prognostic biological significance of cuproptosis-related genes In current study, we examined transcriptional clinical data 13 patients with cancer from TCGA database. We found that DLAT, SLC31A1, ATP7A ATP7B were significantly related overall survival (OS) univariate Cox regression analysis. Unlike lung or kidney cancers, SLC31A1 expression was upregulated samples compared normal tissues, predicted poor prognosis. Univariate multivariate analyses indicated high level an independent factor shorter OS. A nomogram integrating age, T-, N-stage stage constructed, calibration curves 1-, 3-, 5-, 10-year OS fitted well ideal model. Furthermore, deregulated immune response metabolic pathways. Low sensitivity CTLA4 inhibitors but paclitaxel. Our may provide novel insights copper homeostasis cuproptosis

Язык: Английский

---